STOCK TITAN

Evommune reprices CFO Kyle Carver's stock options

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Evommune, Inc. Chief Financial Officer Kyle Carver reported a one-time repricing of two outstanding stock options on November 13, 2026. The 279,408-share option with a $16.00 original exercise price and the 98,946-share option with a $26.77 original exercise price were deemed canceled and replaced with options for the same respective share counts at a $7.63 exercise price per share.

If either replacement option is exercised before the earliest of November 13, 2027, a Change in Control, or specified death, Disability, termination without Cause, or resignation for Good Reason events, the premium exercise price equals the option’s original exercise price. The first option was originally granted November 5, 2025, and the second April 16, 2026.

Insider Carver Kyle
Role Chief Financial Officer
Type Security Shares Price Value
Disposition Stock Option (Right to buy) F1, F2, F3 279,408 -- --
Grant/Award Stock Option (Right to buy) F1, F2, F3 279,408 -- --
Disposition Stock Option (Right to buy) F4, F2, F5 98,946 -- --
Grant/Award Stock Option (Right to buy) F4, F2, F5 98,946 -- --
Holdings After Transaction: Stock Option (Right to buy) — 378,354 options (Direct)
Holdings Before and After: Stock Option (Right to buy), 378,354 to 378,354 options (Direct)
Footnotes (5)
  1. F1. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on November 5, 2025 and is partially vested.
  2. F2. The transaction reported herein reflects a one-time stock option repricing (the "Option Repricing") pursuant to which the exercise price of the reported option has been amended to reduce the exercise price to $7.63 per share. If the Reporting Person exercises this option prior to the earliest of: (i) November 13, 2027; (ii) a Change in Control, as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"); and (iii) the Reporting Person's death or Disability or termination of employment by the Issuer without Cause (each as defined in the 2025 Plan) or resignation following a Change in Control for Good Reason (as defined in the Reporting Person's employment agreement, if applicable), then the Reporting Person will be required to pay a premium exercise price equal to the original exercise price per share of such option.
  3. F3. One fourth (1/4) of the shares subject to the option award vested on November 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
  4. F4. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 16, 2026.
  5. F5. One fourth (1/4) of the shares subject to the option award shall vest on April 16, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
First option shares 279,408 shares Option originally granted November 5, 2025; deemed canceled and replaced
First option original exercise price $16.00 per share Original exercise price before repricing
Second option shares 98,946 shares Option originally granted April 16, 2026; deemed canceled and replaced
Second option original exercise price $26.77 per share Original exercise price before repricing
Replacement option exercise price $7.63 per share Repriced exercise price, subject to the premium exercise-price condition
Initial vesting portion One fourth of the shares Vesting schedule for each option
Remaining vesting installments 36 equal monthly installments Vesting schedule for each option after the initial portion
Early-exercise date threshold November 13, 2027 One of the events used to determine whether the premium exercise price applies
Option Repricing financial
"one-time stock option repricing (the “Option Repricing”)"
premium exercise price financial
"required to pay a premium exercise price equal to the original exercise price per share"
2025 Equity Incentive Plan technical
"as defined in the Issuer’s 2025 Equity Incentive Plan"
Change in Control technical
"a Change in Control, as defined in the Issuer’s 2025 Plan"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
Disability technical
"death or Disability or termination of employment by the Issuer without Cause"
Good Reason technical
"resignation following a Change in Control for Good Reason"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How do Kyle Carver’s repriced EVMN options vest?

The option originally granted November 5, 2025, had one-fourth of its shares vest on November 5, 2026, with the rest vesting in 36 equal monthly installments. One-fourth of the option originally granted April 16, 2026, is scheduled to vest on April 16, 2027, with the rest vesting in 36 equal monthly installments. Vesting is subject to continuous service.

When do Kyle Carver’s repriced EVMN options require a premium exercise price?

An exercise before the earliest of November 13, 2027, a Change in Control, or specified events involving death, Disability, termination without Cause, or resignation for Good Reason requires a premium exercise price equal to the option’s original exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Carver Kyle

(Last)(First)(Middle)
C/O EVOMMUNE, INC.
1891 PAGE MILL ROAD

(Street)
PALO ALTO CALIFORNIA 94304

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to buy)$1611/13/2026D(1)279,408 (3)11/04/2035Common Stock279,408(2)0.00D
Stock Option (Right to buy)$7.6311/13/2026A(1)279,408 (3)11/04/2035Common Stock279,408(2)279,408D
Stock Option (Right to buy)$26.7711/13/2026D(4)98,946 (5)04/15/2036Common Stock98,946(2)0.00D
Stock Option (Right to buy)$7.6311/13/2026A(4)98,946 (5)04/15/2036Common Stock98,946(2)98,946D
Explanation of Responses:
1. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on November 5, 2025 and is partially vested.
2. The transaction reported herein reflects a one-time stock option repricing (the "Option Repricing") pursuant to which the exercise price of the reported option has been amended to reduce the exercise price to $7.63 per share. If the Reporting Person exercises this option prior to the earliest of: (i) November 13, 2027; (ii) a Change in Control, as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"); and (iii) the Reporting Person's death or Disability or termination of employment by the Issuer without Cause (each as defined in the 2025 Plan) or resignation following a Change in Control for Good Reason (as defined in the Reporting Person's employment agreement, if applicable), then the Reporting Person will be required to pay a premium exercise price equal to the original exercise price per share of such option.
3. One fourth (1/4) of the shares subject to the option award vested on November 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
4. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 16, 2026.
5. One fourth (1/4) of the shares subject to the option award shall vest on April 16, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Remarks:
/s/ Gregory S. Moss, Attorney-in-Fact11/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading